All Updates

All Updates

icon
Filter
Partnerships
QIAGEN and Myriad Genetics collaborate to develop NGS test kits for cancer diagnostics
Precision Medicine
May 30, 2024
This week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 30, 2024

QIAGEN and Myriad Genetics collaborate to develop NGS test kits for cancer diagnostics

Partnerships

  • QIAGEN, in collaboration with Myriad Genetics, has announced the development of a globally distributable next-generation sequencing (NGS) test kits for analyzing Homologous Recombination Deficiency (HRD) status in cancer patients.

  • The test is powered by QIAGEN’s proprietary QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary MyChoice CDx. The development project was initiated under the partnership between the two companies in October 2023.

  • According to the agreement, QIAGEN will gain the development and distribution rights of the product outside of the US. Financial terms of the transaction were undisclosed. The company will also be granted intellectual property rights to collaborate with pharmaceutical partners to create a companion diagnostic IVD-validated test to be used outside of the US.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.